Phase II clinical study of leucovorin in combination with pralatrexate in Japanese relapsed/refractory peripheral T-cell lymphoma patients

MUNDIPHARMA K.K.1 个研究点目标入组 13 人开始时间: 待定最近更新: 2021年12月8日

适应症

试验速览

暂无简介。

•Patients with a histologically confirmed diagnosis of PTCL who have received at least one prior treatment and have relapsed/refractory disease
•Patients who have a measurable lesion confirmed by CT or PET-CT test
•Patients who are expected to survive for at least 3 months from study enrollment
•Patients with ECOG PS from 0 to 2
•Patients maintaine each internal organs function
•Patients who have given written informed consent prior to initiation of this study

•Patients who received any treatment of PTCL within 21 days prior to the initial administration of pralatrexate in this clinical study, or who have not completely recovered from the toxicities of such prior therapies with unstable medical conditions
•Patients who have stomatitis
•Patients with active CNS involvement or cerebral metastasis
•Patients who have NYHA classification III/IV congestive heart failure, poorly controlled arrhythmias or unstable angina pectoris
•Patients who have infectious disease requiring intravenous administration of antibacterial agent, fungicide, or antiviral drug
•Patients who tested positive for HBs antigen or HIV antibody. Or patients who tested positive for either HBs antibody or HBc antibody, and showed HBV DNA levels above the upper limit of quantification for the assay. Or patients who tested positive for HCV antibody, and showed HCV RNA levels above the upper limit of quantification for the assay
•Patients with hypersensitivity to pralatrexate, leucovorin, vitamin B12 or folic acid
•Pregnant women, lactating women, or women who may be pregnant

efficacy The incidence of Grade 2 or higher stomatitis occurred in Cycle 1.

未报告次要终点

发起方

MUNDIPHARMA K.K.

Loading locations...